DelveInsight Business Research LLP

DelveInsight has launched a new report on “Chemotherapy Induced Neutropenia – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Chemotherapy Induced Neutropenia – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Chemotherapy Induced Neutropenia, historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Chemotherapy Induced Neutropenia Market Report:

1. In the 7MM, the total estimated number of cancer patients on chemotherapy was 1,790,618 in 2020. 

2. In 2020, the highest number of cancer patients on chemotherapy were accounted for by the US making up to 691,906, while the EU5 countries accounted for 778,973 cancer patients on chemotherapy. Japan ranked second among 7MM countries with 319,740 cancer patients on chemotherapy in 2020.

3. Assessments as per DelveInsight show that there were 484,334 cases at intermediate-high risk for CIN,  and 207,572 cases at low risk for CIN in the United States, in 2020.

4. In 2020, the total number of cases of CIN in the 7MM was 903,597. The US accounted for a majority of cases in the 7MM with 383,339 cases.

Key benefits of the report:

1. The Chemotherapy Induced Neutropenia market report covers a descriptive overview and comprehensive insight of the Chemotherapy Induced Neutropenia Epidemiology and Chemotherapy Induced Neutropenia  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Chemotherapy Induced Neutropenia market report provides insights on the current and emerging therapies.

3. Chemotherapy Induced Neutropenia market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Chemotherapy Induced Neutropenia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chemotherapy Induced Neutropenia market.

Got queries? Click here to know more about the Chemotherapy Induced Neutropenia Market Landscape.

Chemotherapy Induced Neutropenia Overview

Neutrophils belong to the phagocyte system and represent the first cellular components of the inflammatory response and key components of innate immunity. Most healthy people have an absolute neutrophil count (ANC) of approximately 1,500–7000/mmᶾ of blood. When levels of neutrophils drop below 1,500/mmᶾ of blood, the condition is called neutropenia. As a consequence of systemic cancer treatment, neutropenia is the most common and potentially serious hematological complication in cancer patients undergoing chemotherapy. Neutropenia of this etiology is commonly known as chemotherapy-induced neutropenia (CIN).

Chemotherapy-induced neutropenia (CIN) is the primary dose-limiting toxicity in patients with cancer treated with chemotherapy. It can lead to febrile neutropenia (FN), and it is associated with increased morbidity and early mortality, increased medical costs, and disruptions in potentially curative treatments. The risk of infection in Chemotherapy-induced neutropenia patients ranges between 10% and 50% for patients with solid tumors and more than 80% for hematological malignancies. Several risk factors for Chemotherapy-induced neutropenia include older age, female gender, poor performance status, albumin level

Chemotherapy Induced Neutropenia Market 

The dynamics of the Chemotherapy Induced Neutropenia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Spectrum Pharmaceuticals, Enzychem Lifesciences Corporation, Aileron Therapeutics, Cellerant Therapeutics, Myelo Therapeutics, BeyondSpring Pharmaceuticals, Evive Biotech, and others during the forecasted period 2018-2030.

Chemotherapy Induced Neutropenia Pipeline Therapies and Key Companies 

1. Rolontis (eflapegrastim injection): Spectrum Pharmaceuticals

2. EC-18: Enzychem Lifesciences Corporation

3. ALRN-6924: Aileron Therapeutics

4. Romyelocel-L/CLT-008: Cellerant Therapeutics

5. Myelo001: Myelo therapeutics

6. Plinabulin: BeyondSpring Pharmaceuticals

7. F-627 (Ryzneuta): Evive Biotech 

Chemotherapy Induced Neutropenia Market drivers

1. Robust pipeline

2. Rising incidence of cancer

3. Rising awareness

4. Novel therapy development

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Chemotherapy Induced Neutropenia Patient Share (%) Overview at a Glance

5. Chemotherapy Induced Neutropenia Market Overview at a Glance

6. Chemotherapy Induced Neutropenia Disease Background and Overview

7. Chemotherapy Induced Neutropenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Chemotherapy Induced Neutropenia 

9. Chemotherapy Induced Neutropenia Current Treatment and Medical Practices

10. Unmet Needs

11. Chemotherapy Induced Neutropenia Emerging Therapies

12. Chemotherapy Induced Neutropenia Market Outlook

13. Country-Wise Chemotherapy Induced Neutropenia Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Chemotherapy Induced Neutropenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Chemotherapy Induced Neutropenia Market Outlook 2030 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/